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neuronal and neuroendocrine cells in the central nervous system, 
as well as in the generation of olfactory and autonomic neurons 
(Howard, 2005). The function of Mash1 is closely linked to paired-
like homeobox 2a (Phox2a) and Phox2b, two factors that regu-
late expression of tyrosine hydroxylase (TH) and dopamine beta 
hydroxylase (DBH), respectively (Zellmer et al., 1995; Yang et al., 
1998; Howard, 2005).
Retrovirus-mediated expression of hASH1 caused a change in 
the fate of adult hippocampal stem/progenitor cells in favor of the 
generation of oligodendrocytic lineage cells (Jessberger et al., 2008). 
Furthermore, forced expression of Ascl1 was sufficient to induce 
immature, neuronal features in mouse fibroblasts. The additional 
expression of Brn2 (brain-specific homeobox/POU domain pro-
tein 2) and Myt1l (myelin transcription factor 1-like) converted 
mouse embryonic and postnatal fibroblasts into functional neurons 
in vitro (Vierbuchen et al., 2010).
Mash1 knock-out mice die within 24 h after birth (Guillemot 
et al., 1993). Deletion of Mash1 impaired the generation of sym-
pathetic, parasympathetic, and enteric neurons as well as neural 
progenitor cells, especially in the olfactory sensory epithelium and 
the ventral telencephalon (Guillemot et al., 1993; Hirsch et al., 
1998; Lo et al., 1998; Casarosa et al., 1999; Horton et al., 1999; 
Cau et al., 2002; Wildner et al., 2006). Furthermore, mutations in 
the ASCL1 gene are associated with the congenital central hypov-
entilation syndrome (CCHS) phenotype (de Pontual et al., 2003; 
Sasaki et al., 2003).
IntroductIon
During neuronal development the spatial and temporal fulfillment 
of specific gene expression programs is crucial for the formation 
of normal size, shape and integrity of the brain structures. This 
process is critically controlled by a set of basic helix-loop-helix 
(bHLH) transcription factors (Kageyama et al., 2005). It has been 
hypothesized that all neural stem cells gain neurogenic compe-
tency at a certain point, and that repressor-type bHLH factors (e.g., 
Hes1; hairy and enhancer of split 1) brake the neurogenic process 
by repressing the activator-type bHLH genes and thereby coordi-
nate the neuronal differentiation program (Kageyama et al., 2005). 
Moreover, homeodomain and zinc-finger DNA-binding proteins 
function in concert to modify or regulate the activity of bHLH 
factors (Howard, 2005). Once induced, combined activation of 
bHLH genes can specify different types of neurons from those 
induced by each bHLH transcription factor alone (Kageyama et al., 
2005). Thus, the neuronal development and cell fate determination 
is quite complex.
Human achaete-scute homolog-1 (hASH1) belongs to the 
activator-type of the bHLH transcription factor family. The 
ASCL1 gene product is designated hASH1 for the human form 
and Mash1 for the mammalian homolog. The latter term is com-
monly used for the corresponding mRNA/protein in rodents. It has 
been shown that expression of the pro-neural gene ASCL1 com-
mits cells to a neuronal fate (Guillemot et al., 1993). Thus, Mash1 
plays an important role in the commitment and   differentiation of 
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the ASCL1 gene is associated with various tumors, including lung 
cancer, neuroendocrine tumors, carcinoid tumors, and pancreatic 
adenocarcinomas, among others (Ito et al., 2001; Axelson, 2004; Ball, 
2004), and cellular tumorigenicity could be modulated by Mash1 
(Jiang et al., 2009). The role of ASCL1 in neuroblastomas, which 
reflect an early arrest of neuronal differentiation, is controversial: 
While it has been reported that ASCL1 is highly expressed in undif-
ferentiated neuroblastomas (Bourdeaut et al., 2009), ASCL1 was not 
increased in neuroblastoma with unfavorable outcome in another 
investigations (Gestblom et al., 1999; Ichimiya et al., 2001).
Recently, several Mash1 target genes have been identified (Gohlke 
et al., 2008; Johansson et al., 2009). However, although the crucial 
function of Mash1/hASH1 in cell fate determination, neurogen-
esis, and tumorigenesis has been well documented, little is known 
regarding conditions, trans-factors, and mechanisms that modulate 
its gene expression rate. It has been shown that Mash1/hASH1 
is tightly regulated by the Notch [Drosophila Notch homolog 1 
(controlling the ectodermal and neural cell fate in Drosophila)] 
pathway. Activation of Notch receptors cause their interaction 
with the DNA-binding protein RBP-Jk and subsequent enhanced 
expression of HES-1, which, in turn, represses downstream tar-
get genes such as ASCL1 (Chen et al., 1997; Apelqvist et al., 1999; 
Axelson, 2004). Furthermore, Notch1 has been suggested to stimu-
late accelerated hASH1 protein turnover by increased proteasomal 
degradation (Sriuranpong et al., 2002). We recently demonstrated 
that ASCL1 gene expression can be further modulated by post-
transcriptional mechanisms affecting the hASH1 mRNA transla-
tion rate (Fähling et al., 2009).
Regulation of gene expression rate at the post-transcriptional 
level is mainly attributed to the interaction of trans-factors, i.e., 
RNA-binding proteins (RNA-BPs) or microRNAs (miRNAs), with 
cis-elements, that are mainly located in the mRNA untranslated 
regions (UTRs; Bolognani and Perrone-Bizzozero, 2008; Martino 
et al., 2009). These trans-factors modulate the stability, subcellular 
localization and efficiency of translation of bound transcripts.
To obtain insights into the molecular mechanisms of hASH1 
regulation, we searched for conditions that would change ASCL1 
gene expression rates with a special effort on post-transcriptional, 
hASH1 mRNA UTR mediated, control. For this purpose human 
neuroblastoma-derived Kelly cells were used, which express hASH1 
at constantly high level and may thus contain all essential factors 
necessary for hASH1 expression. Initial experiments revealed that 
phorbol 12-myristate 13-acetate (PMA) treatment of Kelly cells 
caused a fast, strong and long-lasting inhibition of hASH1 syn-
thesis. Phorbol-esters are known to induce differentiation proc-
esses but also promote tumor growth, both conditions that are 
related to hASH1 function. The aim of this study therefore was 
to investigate the mechanisms how phorbol-esters may inhibit 
hASH1 expression.
MaterIals and Methods
cell culture
Human neuroblastoma-derived Kelly cells (ACC 355) were 
obtained from the American Type Culture Collection (ATCC) 
and grown at 37°C, 5% CO2 in 60-mm dishes in RPMI medium 
(PAA Laboratories, Pasching, Austria) supplemented with 10% 
fetal calf serum (FCS; Biochrom KG, Berlin, Germany), 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 1% glutamate (all from 
Invitrogen, Karlsruhe, Germany). If not otherwise stated, Kelly cells 
were treated with 40 nM PMA solved in ethanol. In control experi-
ments the cells were incubated with the solvent alone.
For the preparation of primary neurons time-pregnant rats were 
sacrificed according to the permit (LaGeSo, 0122/07) given by the 
Office for Health Protection and Technical Safety of the regional 
government of Berlin and in compliance with regulations laid down 
in the European Community Council Directive. Cortex cells from 
E19 Wistar rats were prepared as previously described for hip-
pocampal neurons (Eichler et al., 2008) and maintained for 8 days 
in vitro in B27- and 1% FCS-supplemented Neurobasal medium 
(Brewer and Cotman, 1989). The initial cell density of cortex cells 
from E19 Wistar rats was 68,000/cm2. On day 2 in vitro (d.i.v. 2), 
cells were incubated for 6 h with 20 nM PMA solved in ethanol, and 
the control culture was treated with 0.2% of the solvent.
IMMunofluorescence
In cortex cell cultures from E19 Wistar rats the Mash1 protein was 
visualized using a monoclonal mouse antibody (MASH1, 1:500, BD 
Biosciences, USA). The secondary antibody (affinity purified and 
multi-labeling declared) coupled to tetramethylrhodamine isothio-
cyanate (TRITC) was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA, USA). Neurons were fixed using an 
ice-cold mixture of 4% paraformaldehyde (PFA) and 4% sucrose 
in phosphate-buffered saline (PBS; 15 min at room temperature). 
After three wash steps in PBS coverslips were incubated overnight 
in PBS/gelatin at 4°C, prior to staining with antibodies. First and 
secondary antibodies were incubated at room temperature for 1 h 
and 45 min, respectively. In between antibody incubations, cover-
slips were washed four times, each, with PBS/gelatin. Coverslips 
were finally mounted on microscope slides using DAPI-containing 
Vectashield medium for visualization of cell nuclei (Vector 
Laboratories, Burlingame, CA, USA).
Labeled neurons were visualized with a standard epifluores-
cence microscope (Olympus BX51, Olympus Deutschland GmbH, 
Hamburg, Germany) under U Plan FL N 10.0× objective (Olympus). 
Appropriate filters (U-MSP100v2 MFISH DAPI and U-MSP102v1 
MFISH Cy3; Olympus GmbH, Germany) allowed the detection 
and separation of fluorescent signals. Images were acquired using 
a 14-bit cooled CCD camera (Spot PURSUIT, Visitron Systems 
GmbH, Puchheim, Germany) and the software Metamorph 
(Universal Imaging Corp., Downingtown, PA, USA).
deterMInatIon of mrna and proteIn levels
Total RNA was isolated from cultured cells using the RNA-Bee™ rea-
gent (AMS Biotechnology, Germany). First-strand cDNA synthesis 
was performed with 2 μg of total RNA using oligo(dT) primers and 
superscript II reverse transcriptase (Invitrogen GmbH, Karlsruhe, 
Germany). Quantitative PCR analysis was performed in triplicate 
with the GeneAmp 5700 system (Applied Biosystems, Darmstadt, 
Germany) according to the manufacturer’s instructions. The fol-
lowing intron bridging primers were used for the amplification 
reactions: hASH1-forward: 5′-CGACTTCACCAACTGGTTCT, 
hASH1-reverse: 5′-CCGTGAATGATTGGAGTGC, beta-ac-
tin-forward: 5′-TGAAGTGGTACGTGGACATC, beta-actin-
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co-transfected with a reporter construct containing the firefly-luci-
ferase gene flanked by the 5′- and/or 3′UTRs of hASH1 mRNA and the 
renilla luciferase phRL-TK vector (Promega, Mannheim, Germany) 
using the Roti® Fect Transfection Reagent (Carl Roth GmbH & Co. 
KG, Karlsruhe, Germany) according to the manufacturer’s protocol. 
Activity levels of renilla luciferase served for normalization of trans-
fection efficiencies. The luciferase activities were measured in a lumi-
nometer (Labsystems Luminoskan RS, Helsinki, Finland).
deterMInatIon of mrna and proteIn half lIfe tIMes
For the estimation of hASH1 mRNA and protein stabilities, human 
neuroblastoma-derived Kelly cells were cultured as described above 
and treated with PMA or solvent (control). Following PMA admin-
istration, cell culture media were supplemented with actinomycin D 
(5 μg/ml), an inhibitor of mRNA transcription to estimate mRNA 
half life, or cycloheximide (20 μg/ml), which blocks mRNA transla-
tion, for determination of hASH1 protein half life times. Incubation 
of the cells was continued for different time periods as indicated. 
RNA and protein lysates were prepared and quantified as described 
before. Decreasing mRNA and protein levels represent the rate of 
decay under the conditions tested.
proteIn kInase InhIbItIon
To assess the influence of the protein kinase C (PKC), cells were 
pre-incubated with either staurosporine (40 nM; #S4400, SIGMA-
ALDRICH, Germany), or GF109203X (5  μM; #B6292, SIGMA-
ALDRICH, Germany) according to the manufacturer’s instructions for 
4 h prior to the treatment with PMA or solvent (control). Furthermore, 
KT-5720 (2 μM; #BML-EI-199, Enzo Life Sciences GmbH, Germany) 
was used for inhibition of protein kinase A (PKA).
statIstIcs
If not otherwise indicated, all values are presented as means ± SD. 
Student’s paired t-test was performed to reveal statistical signifi-
cances. p Values less than 0.05 were considered significant.
results
phorbol 12-MyrIstate 13-acetate suppresses hash1 synthesIs
Administration of PMA (40 nM) caused a fast and long-lasting 
suppression of hASH1 synthesis in Kelly cells. At the mRNA level 
this inhibitory effect was evident after 3 h, during which the hASH1 
mRNA content dropped to 44% compared to control conditions 
(Figure 1). This down-regulation of hASH1 transcripts was rela-
tively stable for up to 24 h. Following 48 h of PMA treatment, the 
hASH1 mRNA level was still moderately reduced (57% compared 
to control). The initial 24 h of incubation with PMA caused a 
decrease of both hASH1 mRNA as well as protein levels. However, 
at 48 h of PMA treatment the hASH1 protein level further dropped 
(to 18% compared to control), whereas hASH1 transcripts tended 
to recover from suppression (Figure 1).
regulatory eleMents MedIatIng pMa Induced hash1 
suppressIon
Gene expression rates are controlled at the transcriptional and post-
transcriptional level by interaction of trans-factors with cis-regu-
latory elements. Post-transcriptional regulation involves changes 
  reverse: 5′-GTCATAGTCCGCCTAGAAGC, GAPDH-forward: 
5′-CACCATCTTCCAGGAGCGAG, GAPDH-reverse: 
5′-GCAGGAGGCATTGCTGAT. The expression levels of hASH1 
mRNA were normalized to beta-actin or GAPDH using the ∆Ct 
method. Parallelism of standard curves of the test and control 
was confirmed.
Cellular protein extracts were prepared from cultured cells as 
described previously (Kirschner et al., 2006) and separated on a 
10% polyacrylamide gel. The proteins were transferred onto poly-
vinylidene difluoride membranes (Amersham Pharmacia Biotech, 
Freiburg, Germany) using a Bio-Rad Mini Trans-Blot transfer cell 
(Bio-Rad, Munich, Germany). Immunodetection of hASH1 was per-
formed according to our routine protocol (Fähling et al., 2006a,b) 
using a 1:500 dilution of the anti-Mash1 primary antibody (#556604, 
BD Biosciences, Heidelberg, Germany). As a loading control detec-
tion of beta-actin (#MAB1501R, Chemicon, Schwalbach, Germany; 
dilution 1:1.000) and GAPDH (#BM439, Acris Antibodies GmbH, 
Hiddenhausen, Germany; dilution: 1:1.500) was performed. The 
reference antibodies were applied after stripping of the membranes 
with bi-distilled water for 5 min, 0.2 M NaOH for up to 5 min and 
a final wash with bi-distilled water for 5 min. Primary antibodies 
were detected with peroxidase-coupled secondary antibodies, and 
the reaction products were visualized with the enhanced chemi-
luminescence system (Amersham Pharmacia Biotech, Freiburg, 
Germany). Autoradiographic signals were scanned and quantified 
using the Scion Image software (Scion Corporation).
Quantification of Mash1 fluorescence (signal) was achieved 
using intensity measurements within circular regions of interest 
(diameter 5 μm) projected on the center of nuclei. Background 
fluorescence (noise) was quantified likewise, except that cell-free 
regions of interest were chosen. For convenience, the original 
intensity values (ranging from 0 to 255, with “0” representing 
white perception and “255” black color) were subtracted from 
the value of 255 so that increasing intensity values indicate increas-
ing fluorescence intensities. Statistical analysis (unpaired Student’s 
t-test) was performed using the software Origin (MicroCal, 
Northampton, MA, USA).
plasMIds
A 1436-bp fragment of the predicted ASCL1 gene promoter sequence 
(NCBI number U77616) was cloned by PCR and ligated into the 
pGL3basic reporter vector (Promega GmbH, Mannheim, Germany). 
Likewise, we also obtained a 1132-bp fragment carrying the murine 
Ascl1 promoter (Ensembl gene ENSMUSG00000020052).
For the generation of luciferase reporter constructs that express 
the firefly-luciferase in a hASH1 mRNA UTRs dependent man-
ner, the pGL3promotor vector (Promega GmbH, Mannheim, 
Germany), which contains a constitutive SV40 promoter, was 
modified by replacement of the vector specific 5′- and 3′UTRs of 
luciferase mRNA by the human hASH1 mRNA UTRs as described 
in Fähling et al. (2009). The quality of processed vectors was con-
firmed by sequencing.
cell transfectIon and reporter gene assays
Transient transfections of Kelly cells were performed as described 
previously (Fähling et al., 2009). Briefly: cultured cells were grown to 
approximately 70% confluence in 96-well plates (μClear Platte 96K, 
Frontiers in Molecular Neuroscience  www.frontiersin.org  February 2011  | Volume 4  | Article 1  |  3
Benko et al.  Phorbol-ester mediated hASH1 suppression24 h were observed in transfected Kelly cells. Only prolonged (48 h) 
PMA treatment reduced the luciferase activity, indicating a delayed 
inhibitory effect of PMA on the ASCL1 promoter (Figure 2A).
In contrast, hASH1 mRNA UTR-dependent reporter gene assays 
indicated a post-transcriptional inhibition which started approxi-
mately at 6 h and became significant after 12 h of PMA treatment 
(Figure 2B). The suppressing influence reached similar levels (down to 
approximately 30% compared to control) as found at the native hASH1 
mRNA and protein levels. Interestingly, the hASH1 mRNA UTR medi-
ated suppression of protein synthesis was constant up to 48 h.
Responsible regulatory elements may be located either in the 
hASH1 mRNA 5′- or 3′UTR. Therefore, we separately tested the 
influence of the hASH1 mRNA 5′UTR and 3′UTR. It turned out 
that both, the 5′- as well as the 3′UTR have independent inhibitory 
properties (Figure 3). The combination of 5′- and 3′UTR, however, 
Figure 1 | Human achaete-scute homolog-1 mrNA and protein levels 
following PMA (40 nM) treatment. (A) Determination of hASH1 mRNA 
levels by qRT-PCR (n = 9). (B) Statistical analysis of hASH1 protein levels 
obtained by Western Blotting (n = 6). (C) Representative Western blot 
analysis. Pools of six independent samples per condition are shown. Control 
cells were treated with PMA solvent (ethanol). Detection of GAPDH and 
beta-actin served as loading controls. Shown are mean values, and error bars 
represent the standard deviation (SD). *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2 | reporter gene assays. Kelly cells were transiently transfected 
(36 h) with reporter gene vectors containing either the ASCL1 promoter 
sequence or the hASH1 mRNA 5′- and 3′UTRs followed by PMA 
administration (40 nM). In hASH1 mRNA UTR-dependent reporter assays the 
firefly-luciferase transcription rate was controlled by the constitutive SV40 
promoter. Values of firefly-luciferase activity were normalized to the 
co-transfected renilla-luciferase. (A) Influence of ASCL1 promoter on 
PMA-mediated reporter gene activity. (B) hASH1 mRNA 5′- and 3′UTR-
dependent response on gene expression rate following PMA treatment. 
n = 12; *p < 0.05, **p < 0.01, ***p < 0.001.
in mRNA stability, mRNA translation rate or mRNA localization, 
which is attributed to RNA-BPs or miRNAs interacting mainly 
with the mRNA UTRs (Kuersten and Goodwin, 2003). Reporter 
gene assays were applied to search for potential regulatory elements 
in the ASCL1 promoter and in the mRNA UTRs. No significant 
changes in ASCL1 promoter activity following PMA treatment for 
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reporter gene assays, whereas Forskolin an activator of the adeny-
lyl cyclase/PKA signaling pathway (Insel and Ostrom, 2003), did 
not. Furthermore, substances commonly used to induce a chemical 
hypoxia such as cobaltous chloride [competes with iron (Fe2+)] or 
2,2′-Dipyridyl (which chelates Fe2+) significantly suppressed the 
reporter gene activity.
MechanIsMs Involved In hash1 InhIbItIon
From the mechanistic point of view the data gathered so far indicate 
that hASH1 mRNA UTR mediated control may cause an alteration 
in hASH1 mRNA stability at early time points (up to 24 h). This 
is supported by mRNA stability assays (Figure 5A). After treat-
ment with actinomycin D which blocks mRNA transcription, the 
mRNA degradation rate was significantly higher in PMA-treated 
cells (6 h) compared to control cells (1.02 ± 0.04 h for control and 
0.46 ± 0.03 h for PMA-treated cells). At 48 h, however, the hASH1 
mRNA half life was similar under both conditions (1.07 ± 0.06 h 
for control and 1.18 ± 0.09 h for PMA treatment; Figure 5B). Thus, 
the reduced hASH1 mRNA level during prolonged PMA treatment 
seems to be determined by inhibition of mRNA transcription, as 
indicated by ASCL1 promoter assays (Figure 2B).
Following 48 h of PMA treatment, the hASH1 protein level fur-
ther dropped (from 30% at 24 h to 11% at 48 h; Figure 1B), which 
is in contrast to the partial recovery of hASH1 mRNA from PMA-
dependent inhibition after 48 h (Figure 1A). The latter observation 
could be explained either by alteration in the hASH1 protein half 
life or inhibition of hASH1 mRNA translation rate.
We therefore determined the hASH1 protein half life under 
prolonged conditions (48 h). It turned out that protein turnover 
was similar under control condition and following PMA treatment 
(1.12 ± 0.13 h for control and 1.2 ± 0.2 h for PMA treatment; 
Figures 5C,D). Considering that hASH1 mRNA UTR-dependent 
reporter gene assays showed an inhibition under prolonged condi-
tions, which cannot be attributed to an alteration in mRNA stability 
(Figure 5B), these data implicate that hASH1 mRNA translation is 
inhibited by PMA treatment at 48 h PMA.
Taken together, these data suggest that reduced hASH1 mRNA 
levels up to 24 h of PMA treatment result from reduced mRNA 
stability. At 48  h of PMA decreased ASCL1 promoter activity 
reflects inhibition of gene transcription. Furthermore, under pro-
longed conditions suppressed hASH1 protein levels seem to be also 
  attributed to reduced hASH1 mRNA translation.
Both, hASH1 mRNA and -protein half lifes are very short 
(approximately 1 h each), indicating a high turnover rate, which 
is about one-third only of that determined for the firefly-luciferase 
(as reported by Promega Inc.). This might explain the delay in 
the PMA-mediated response observed by hASH1 mRNA UTR-
dependent reporter gene assays compared to native hASH1 mRNA 
and protein levels (see Figures 1 and 2).
role of proteIn kInase c In the control of hash1 synthesIs
Phorbol 12-myristate 13-acetate is a known activator of the PKC 
(Liu and Heckman, 1998). We therefore asked whether tran-
scriptional and/or post-transcriptional responses in the altera-
tion of hASH1 synthesis mediated by PMA are attributed to the 
action of PKC.
caused the strongest suppressing effect which seems to be additive. 
This observation suggests that trans-factors interacting at the 5′ or 
3′UTR are necessary for the full inhibitory effect of PMA.
We then determined the optimal PMA dose for the suppressing 
influence of hASH1 mRNA 5′-/3′UTR combination. Four nanomo-
lars PMA (24 h) was already sufficient to suppress the reporter gene 
activity significantly, and 40 nM PMA exerted the strongest effects 
(Figure A1 in Appendix).
The specificity of hASH1 mRNA UTR-dependent reporter 
gene assays was demonstrated by the comparison of different 
substances. A set of results is shown in Figure 4. We found that, 
Figure 3 | influence of hASH1 mrNA 5′- and 3′uTrs in PMA-mediated 
post-transcriptional control. Kelly cells were transiently transfected with 
reporter constructs where the 5′- or 3′UTR of firefly-luciferase mRNA were 
separately replaced by the hASH1 5′- (5′-Luc) or 3′UTR (Luc-3′). The 
firefly-luciferase mRNA flanked by both, the hASH1 mRNA 5′- and 3′UTR 
(5′-Luc-3′) showed the strongest suppressing influence in response to PMA 
treatment (40 nM). n = 12; **p < 0.01, ***p < 0.001.
Figure 4 | Screening for conditions leading to an alteration in gene 
expression rate mediated by hASH1 mrNA 5′- and 3′uTrs. Kelly cells 
were transiently transfected (36 h) with reporter constructs where the 
luciferase mRNA UTRs were replaced by the hASH1 mRNA UTRs. 
Transcription rate was controlled by the constitutive SV40 promoter. Cells 
were treated with different compounds for 24 h. The concentrations used 
were: PMA = 40 nM; Forskolin = 100 nM; adenosine = 100 nM; cobaltous 
chloride (CoCl2) = 50 nM; 2,2′-Dipyridyl (2,2 DP) = 100 mM; ascorbic 
acid = 100 mM; dopamine = 100 nM. Data are relative to the relevant control 
conditions (H2O, ethanol, DMSO respectively). n = 12; **p < 0.01, 
***p < 0.001.
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To establish a broader cellular context for PMA regulation of 
hASH1 we investigated whether PMA suppresses Mash1 (the rodent 
homolog) protein levels also in primary cortical neurons. For this 
purpose we visualized Mash1 in cortical neurons isolated from E19 
Wistar rats and found that PMA decreased the Mash1 level signifi-
cantly according to immunofluorescence (Figure 8) and Western 
blot analysis (Figure A3 in Appendix). At 2 days in vitro, Mash1 was 
expressed in cortical cells (Figure 8A), and PMA indeed reduced 
Mash1 protein (Figure 8B). In control condition, Mash1 expression 
exhibited cellular heterogeneity, which was not observed upon PMA 
treatment (Figure 8C; standard deviation, SD).
dIscussIon
The bHLH transcription factor hASH1 plays an important role in the 
control of neuronal development and differentiation (Bertrand et al., 
2002; Ross et al., 2003; Howard, 2005) and seems also be involved in 
certain types of cancer (Osada et al., 2008; Jiang et al., 2009).
To assess the impact of PKC, Kelly cells were pre-incubated with 
the PKC inhibitors GF109203X or staurosporine for 4 h prior to 
PMA administration. Both inhibitors diminished the PMA-
mediated suppression of hASH1 expression (Figure 6). However, 
neither GF109203X nor staurosporine completely abolished the 
PMA effect, indicating that, in addition to PKC, other factors also 
participate in hASH1 regulation following PMA administration. 
In this context it is important to note that GF109203X and stau-
rosporine differently affect hASH1 mRNA level in the absence of 
PMA (Figure A2 in Appendix).
The influence of PKC inhibition was confirmed in hASH1 mRNA 
UTR-dependent reporter gene assays (Figure 7), suggesting that PKC 
modulates trans-factors acting at the post-transcriptional level of 
hASH1 synthesis. In contrast, inhibition of PKA did not influence 
PMA-mediated suppression of hASH1 mRNA UTR-dependent 
reporter gene activity. Interestingly, while staurosporine dimin-
ished the PMA-mediated suppression only moderately, treatment of 
GF109203X abolished the effect of PMA to a non-significant level.
Figure 5 | estimation of hASH1 mrNA and protein half life. Kelly cells were 
incubated for 6 or 48 h under control conditions or were treated with PMA (40 nM). 
Following solvent/PMA pre-incubation cell culture media were supplemented with 
either actinomycin D to assess hASH1 mRNA half life or cycloheximide for the 
estimation of hASH1 protein stability. (A) hASH1 mRNA stability at 6 h control vs. 
PMA. mRNA half lifes are: control = 1.02 ± 0.04 h; PMA = 0.46 ± 0.03 h. (B) hASH1 
mRNA stability at 48 h control vs. PMA. mRNA half lifes are: control = 1.07 ± 0.06 h; 
PMA = 1.18 ± 0.09 h. (C) Western blot analysis. A representative data set is shown. 
(D) Statistical evaluation of hASH1 protein stability at 48 h control vs. PMA. Protein 
half lifes are: control = 1.12 ± 0.13 h; PMA = 1.2 ± 0.2 h. n = 3.
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Benko et al.  Phorbol-ester mediated hASH1 suppressionWe observed a fast and strong decrease of the amount of hASH1 
mRNA shortly after PMA administration, as determined by real-
time PCR quantification. These findings are consistent with data 
reported previously (Soderholm et al., 1999; Grynfeld et al., 2000). 
The fast decrease in hASH1 mRNA concentration is followed by a 
slight attenuation at longer incubation times (48 h). In contrast, 
the hASH1 protein level continuously declines over the moni-
tored time span. By applying reporter gene assays which contain 
either the hASH1 mRNA UTRs or the ASCL1 promoter, we have 
shown that the rapid down-regulation of hASH1 expression rate is 
attributed to post-transcriptional control. Subsequently performed 
mRNA stability assays revealed that the UTR mediated response 
is a result of hASH1 mRNA destabilization. The half life of cer-
tain transcripts is mainly determined by the size of the poly-A 
tail. Nevertheless, endonucleolytic transcript cleavage-sites, such 
as AU-rich elements (ARE), represent crucial regulatory elements 
(Ross, 1995; Guhaniyogi and Brewer, 2001). Although mRNA sta-
bility is mainly controlled by the mRNA 3′UTR, we found that 
both, the hASH1 mRNA 5′- as well as 3′UTR have independent 
suppressing influences, indicating that multiple trans-factors are 
involved. Interestingly, mRNA destabilization was also found to be 
responsible for down-regulation of the bHLH transcription fac-
tor c-myc under conditions of PMA administration in the human 
leukemia cell line K562 (Brewer, 2000). Similarly to our data, the 
mechanism seems to use an alternate pathway as deadenylation.
A transcriptional suppression of hASH1 synthesis in neurob-
lastoma cells by phorbol-ester has been linked to activation of 
the Notch cascade and subsequent induction of HES1, a potent 
repressor of ASCL1 transcription (Axelson, 2004). Interestingly, the 
down-regulation of hASH1 mRNA level by activated Notch1 can be 
more profound than that by HES1 itself (Sriuranpong et al., 2002). 
These data indicate that decreased hASH1 mRNA in phorbol-ester 
induced cellular differentiation is a result of inhibited mRNA sta-
bilization and mRNA transcription as well. Our findings indicate 
that hASH1 mRNA degradation accounts for the fast response, but 
is abolished under prolonged conditions when the down-regulation 
is mainly due to suppression of the ASCL1 promoter.
We show that under prolonged conditions of PMA adminis-
tration the hASH1 protein level further declines (down to 18% 
compared to control) although the suppression of hASH1 mRNA 
level was less pronounced (57% compared to control), which indi-
cates further mechanisms of gene expression control to be involved. 
UTR-dependent reporter gene assays support the view that, albeit 
the hASH1 mRNA destabilization is already abolished, the hASH1 
mRNA UTRs mediate a suppressing influence. Post-transcriptional 
control of gene expression can be further attributed to an alteration 
of the efficiency of mRNA translation. Thus, the difference between 
hASH1 mRNA and protein levels under prolonged condition may 
be explained by inhibition of hASH1 mRNA translation. However, 
activation of Notch signaling has also been attributed to acceler-
ated hASH1 protein turnover (Sriuranpong et al., 2002). As the 
estimation of mRNA and protein levels represent the net effect of all 
mechanisms activated in gene expression control of a certain gene, 
the data gathered so far suggest that the fast, strong and long-lasting 
suppression of hASH1 synthesis following PMA administration is 
attributed to a couple of trans-factors which act synergistically and, 
at least in part, independently by multiple mechanisms.
We describe here that hASH1 undergoes a rapid suppression 
at the mRNA as well as protein level by administration of PMA 
in human neuroblastoma-derived Kelly cells and in rat primary 
cortex cells, indicating that this mechanism is not specific to a 
particular cell type. Phorbol-esters such as PMA represent sur-
rogates of the second messenger 1,2-diacylglycerol (DAG) and are 
less rapidly degraded, which makes them the preferred activators 
of PKC used in cell culture as well as in in vivo models (Blumberg, 
1991). Phorbol-esters have been implicated in stimulating several 
cellular responses like cell growth, differentiation, or apoptosis. In 
this study, we extend our current knowledge regarding the molecu-
lar mechanisms involved in down-regulation of hASH1 by PMA.
Figure 6 | influence of PKC inhibition on PMA-mediated hASH1 
suppression. Kelly cells were pre-incubated for 4 h with the PKC inhibitors 
GF109203X or staurosporine to block PKC activity. Then, PMA was 
supplemented and cells were harvested after 6, 24, and 48 h of PMA 
administration. hASH1 mRNA levels were estimated by qPCR and normalized 
to the influence of inhibitors alone (see Figure A2 in Appendix for time kinetic 
of PKC inhibitors). n = 9; *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 7 | influence of PKC inhibition on PMA-mediated 
post-transcriptional control of hASH1 mrNA. Kelly cells were transfected 
with a reporter vector containing the hASH1 mRNA 5′- and 3′UTRs as 
regulatory elements that determine the reporter gene expression rate. 
Following 24 h of transfection, cells were pre-incubated either with solvent (--), 
the PKC inhibitors staurosporine or GF109203X, or with the PKA inhibitor 
KT-5720 for 4 h and subsequent administration of PMA (24 h). n = 6; *p < 0.05, 
**p < 0.01; ns, not significant.
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mRNA UTR mediated influence, suggesting PKC dependency, 
whereas staurosporine had a much weaker though significant 
effect. This discrepancy may be explained by the selectivity of 
both compounds. It has been demonstrated that staurosporine 
inhibits other protein kinases in addition to PKC, thus behaves as 
a non-selective inhibitor (Toullec et al., 1991). This is supported 
by our observation that GF109203X and staurosporine differently 
affected hASH1 mRNA level under control conditions (Appendix). 
We found that treatment of Kelly cells with GF109203X caused a 
weak increase in hASH1 mRNA level after 4 h. In contrast, stau-
rosporine treatment resulted in a fast drop in hASH1 mRNA level, 
which was stable up to 48 h. These data suggest that other, PKC-
independent, trans-factors modulate hASH1 expression under 
control conditions. Consistently, one study reported that stau-
rosporine itself can induce differentiation of the neuroblastoma 
cell line NB-1 (Morioka et al., 1985). Moreover, staurosporine-
mediated, PKC-independent, effects might even influence or 
dominate the response of hASH1 mRNA UTRs dependent regu-
lation following PMA administration. Nevertheless, our findings 
indicate that especially the post-transcriptional control of hASH1 
synthesis is PKC dependent. The inhibitory effect of GF109203X is 
achieved through the prevention of ATP binding to PKC and not 
by binding to the phorbol-ester/DAG binding site (Tamaoki et al., 
1986). Therefore, these results might also be of interest under 
conditions of energy depletion. In line with the latter hypothesis 
To get more insights into the molecular pathways, we tested 
whether phorbol-ester induced hASH1 suppression is mediated 
by the activation of the PKC. PKCs represent the most prominent 
targets of phorbol-esters (Liu and Heckman, 1998). The PKC fam-
ily of serine/threonine kinases comprises at least 10 different PKC 
isozymes which can be divided into three different groups based on 
their structural and biochemical properties. Noteworthy, only two 
of these groups, the so called classical PKCs (cPKCs, additionally 
activated by Ca2+) and the novel PKCs (nPKCs, not depending on 
Ca2+), are activated by phorbol-esters. Furthermore, the expressed 
PKC isozyme pattern varies depending on the cell type and tissue 
respectively (Mellor and Parker, 1998; Newton, 2001).
In an attempt to show whether phorbol-ester inducible PKCs 
are involved in the PMA-mediated hASH1 suppression we pre-
incubated the cells for 4 h with staurosporine or GF109203X, both 
known inhibitors of PKC, prior to PMA treatment (Toullec et al., 
1991). Both inhibitors diminished but did not fully prevent the sup-
pressing PMA effect. This suggests that PKC-independent effects 
participate in the PMA-mediated inhibition of hASH1 synthesis. 
Other phorbol-ester targets, which might be involved in the activa-
tion of further signaling pathways, are at least five types of recep-
tors that do not belong to the PKC family but also bear the DAG/
phorbol-ester binding domain C1. These proteins were shown to 
participate in signaling pathways that control cell proliferation, cell 
death, malignant transformation, and the metastatic cascade (Brose 
and Rosenmund, 2002; Yang and Kazanietz, 2003).
Figure 8 | Phorbol 12-myristate 13-acetate induces Mash1 suppression in primary cortical cells. MASH1 expression in d.i.v. 2 control (A) and PMA-treated (B) 
cortex cells is shown. (C) Quantitative analysis of Mash1 intensity. Note that increasing values represent increasing fluorescence intensities. The standard deviation 
(SD) was used as a measure of cellular heterogeneity of Mash1 expression. n = 6 cultures; ***p < 0.001; ns, not significant.
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we observed that iron depletion (by cobaltous chloride or 2,2′-
Dipyridyl), which leads to ATP deficiency, caused suppression 
of reporter gene activity mediated by the hASH1 mRNA UTRs. 
Furthermore, it has been reported that hASH1 synthesis is sup-
pressed in hypoxia (Jogi et al., 2002; McGovern et al., 2010). Thus, 
it can be hypothesized that post-transcriptional control of hASH1 
synthesis involves ATP dependent mechanisms, which may be 
attributed to modulation of PKC activation.
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Figure A1 | Phorbol 12-myristate 13-acetate dose dependent 
suppression mediated by hASH1 mrNA uTrs. Kelly neuroblastoma cells 
were transiently transfected with reporter gene constructs in which the 
luciferase mRNA UTRs were replaced by the hASH1 5′- and 3′UTRs. 
Luciferase activity was measured following 24 h PMA administration. n = 12; 
**p < 0.01, **p < 0.001.
Figure A2 | influence of the PKC inhibitors staurosporine and 
gF109203X on hASH1 mrNA level. Kelly neuroblastoma cells were treated 
with the PKC inhibitors staurosporine or GF109203X and hASH1 mRNA levels 
were estimated by qPCR at different time points. hASH1 mRNA levels were 
normalized to GAPDH. n = 9; *p < 0.05, **p < 0.01, ***p < 0.001.
Figure A3 | Phorbol 12-myristate 13-acetate mediated suppression of 
Mash1/hASH1 protein levels. Isolated primary cortex cells of the rat and 
human neuroblastoma-derived Kelly cells were treated for 6 h with PMA 
(40 nM). Relative Mash1/hASH1 protein levels were quantified by Western 
blot analysis. n = 3; *p < 0.05, ***p < 0.001.
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